SCHEMBL3362226

SCHEMBL3362226

NCCN1Cc2cc(C(=O)c3ccccc3)ccc2N=C1N

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.63
BACE2 Q9Y5Z0 1/20 0.39
PBRM1 Q86U86 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
ABL1 P00519 2/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FABP6 P51161 1/20 0.36
NOX1 Q9Y5S8 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
MAPK1 P28482 1/20 0.35
PDE4A P27815 3/20 0.35
PDE4B Q07343 3/20 0.35
PDE4C Q08493 3/20 0.35
PDE4D Q08499 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28769126 0.88 BACE1 (0.60) BACE1BACE2PBRM1SMN1; SMN2NPC1
SCHEMBL3362216 0.86 BACE1 (0.58) BACE1BACE2PBRM1SMN1; SMN2NPC1
SCHEMBL8267146 0.80 BACE1 (0.64) BACE1BACE2SMN1; SMN2NPC1ALDH1A1
SCHEMBL3363043 0.78 BACE1 (1.00) BACE1PDE4APDE4BPDE4CPDE4D
SCHEMBL3364048 0.77 BACE1 (0.61) BACE1BACE2SMN1; SMN2ALDH1A1PDE4A
SCHEMBL3364055 0.77 BACE1 (0.73) BACE1PDE4APDE4BPDE4CPDE4D
SCHEMBL3367170 0.76 BACE1 (0.59) BACE1BACE2PDE4APDE4BPDE4C
SCHEMBL5350872 0.74 BACE1 (0.36) BACE1BACE2SIGMAR1PDE4APDE4B
SCHEMBL5536001 0.74 BACE1 (0.38) BACE1BACE2PBRM1SMN1; SMN2TDP1
SCHEMBL5507389 0.72 BACE1 (0.55) BACE1BACE2PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436006-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-05-07 US disclosed
US-8426429-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-04-23 US disclosed
US-8383637-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-02-26 US disclosed
EP-1776349-B1 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA NV (BE) 2010-10-06 EP disclosed
US-20060178383-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-10 US disclosed
US-20060079686-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA NV (BE) 2006-04-13 US disclosed
US-20060079687-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178383-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP BACE1 2/4885BACE2 1/4885PBRM1 2864/4885
US-20060079687-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP BACE1 2/4885BACE2 1/4885PBRM1 2864/4885
US-20060079686-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP BACE1 2/4885BACE2 1/4885PBRM1 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.